Robarts Research Institute & VS-CNV

· Andreas Scherer · Customer Success, News, Events, & Announcements

One of our main focuses in 2017 was VS-CNV which allows clinicians to directly call CNVs in target regions quicker, easier and more affordably than CMA or MLPA testing. Our clients at Robarts Research Institute shared their recent publication with me which confirms that our time and dedication to our CNV capabilities was well worth it. I am delighted to share their discoveries with our community.

Michael Iacocca and colleagues analyzed 388 samples of patients with familial hypercholesterolemia, a disease caused predominantly by autosomal codominant mutations in the LDL receptor gene (LDRL). The standard method is to use next-gen sequencing to detect SNVs followed by an MLPA test to identify CNVs. However, their study was interested in seeing if the MLPA portion of the test can be entirely replaced by our NGS-based CNV detection method. It turned out that thirty-eight (9.8%) of the 388 FH patients were positive for CNVs in LDRL according to Golden Helix CNV method. This was 100% in concordance with those detected by MLPA.

The authors concluded the following, “Transitioning to CNV detection from targeted NGS data has many benefits. Our cost for MLPA analysis in LDRL – including reagents, controls, duplicate analysis and labor – was approximately $80 per patient sample, which totaled approximately $31,000 USD for this cohort of 388 FH individuals. These costs would be essentially eliminated when applying a bioinformatics method to NGS data as such data are already generated for small-scale variant analysis that precedes the CNV assessment.”

The calculated savings are based on applying MLPA to only one gene. Most gene panel tests look at a much high number of genes. I encourage you to read the entire study which can be found here.

This finding is in line with similar unpublished findings of other customers and it is supported by our own internal benchmarks. If you have any questions or are interested in learning more about our CNV capabilities, please do not hesitate to reach out. I hope you all have a great start to 2018!

1 Comments

  1. Scientific identification always excites me and I believe we could possible see robots will be replacing all the conventional methods and replace humans in pubic as well in private sectors.

Leave a comment

Andreas Scherer

About Andreas Scherer

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US. He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada.  He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space. Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! 

View all posts by Andreas Scherer →